Antigenically matched influenza vaccines

Patent metadata

Field	Value
Publication number	US-11013795-B2
Application number	US-201615739222-A
Country	US
Kind code	B2
Filing date	Jun 24, 2016
Priority date	Jun 26, 2015
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

Disclosed herein are influenza vaccine compositions, related preparations and intermediates, formulations, production methods, immunization methods, and use thereof, for achieving improved immune-protection in human subjects. More specifically, non-egg-based influenza vaccines are described, which provide improved antigenic match.

First claim

The invention claimed is:

1. A method for immunizing a human who has previously been administered a first influenza vaccine comprising an antigen from a first influenza virus which has been passaged in eggs, comprising administering to the same human a second influenza vaccine comprising an antigen from a second influenza virus which has not been passaged in eggs, wherein the antigen in the second influenza vaccine is more closely antigenically matched to a circulating strain than the antigen in the first influenza vaccine, and wherein the first influenza vaccine and the second influenza vaccine are from one influenza season.

2. A method for immunizing a human, comprising steps of (a) administering to the human a first influenza vaccine comprising an antigen from a first influenza virus which has been passaged in eggs; and subsequently (b) administering to the same human a second influenza vaccine comprising an antigen from a second influenza virus which has been grown in cell culture, wherein the antigen in the second influenza vaccine is more closely antigenically matched to a circulating strain than the antigen in the first influenza vaccine, and wherein the first and the second influenza vaccine are administered within the same influenza season.

3. The method of claim 1 , wherein the second influenza virus has been grown in cell culture.

4. The method of claim 1 , wherein the antigen from the second influenza vaccine is a recombinant protein antigen.

5. The method of claim 1 , wherein the first influenza vaccine is made available prior to the second influenza vaccine.

6. The method of claim 1 , wherein the influenza antigen in the first vaccine is from an influenza virus that has been grown in eggs.

7. The method of claim 1 , wherein the first influenza vaccine is a trivalent influenza vaccine or a tetravalent influenza vaccine.

8. The method of claim 1 , wherein the second influenza vaccine is a monovalent influenza vaccine.

9. A method for immunizing a human who has previously been administered a first influenza vaccine comprising an antigen from a first influenza virus which has been passaged in eggs, comprising administering to the same human a second influenza vaccine comprising an antigen from a second influenza virus which has not been passaged in eggs, wherein the antigen in the second influenza vaccine is more closely antigenically matched to a circulating strain than the antigen in the first influenza vaccine, and wherein the first and the second influenza vaccine are administered within the same influenza season.

10. The method of claim 1 , wherein the second influenza vaccine is free from ovalbumin and ovomucoid.

11. The method of claim 1 , wherein (i) the first influenza vaccine is an inactivated virus vaccine, (ii) the second influenza vaccine is an inactivated virus vaccine, or (iii) the first and the second influenza vaccine is an inactivated virus vaccine.

12. The method of claim 1 , wherein the antigen in the second influenza vaccine was prepared from an influenza virus that has never been passaged in eggs.

13. The method of claim 1 , wherein the first and/or the second influenza vaccine is adjuvanted.

14. The method of claim 13 , wherein the adjuvant is an oil-in-water emulsion adjuvant.

15. The method of claim 1 , wherein the antigen from the second influenza vaccine is manufactured from a synthetic seed virus.

16. The method of claim 2 , wherein the influenza antigen in the first vaccine is from an influenza virus that has been grown in eggs.

17. The method of claim 2 , wherein the first influenza vaccine is a trivalent influenza vaccine or a tetravalent influenza vaccine.

18. The method of claim 2 , wherein the second influenza vaccine is a monovalent influenza vaccine.

19. The method of claim 2 , wherein the second influenza vaccine is free from ovalbumin and ovomucoid.

20. The method of claim 2 , wherein (i) the first influenza vaccine is an inactivated virus vaccine, (ii) the second influenza vaccine is an inactivated virus vaccine, or (iii) the first and the second influenza vaccine is an inactivated virus vaccine.

21. The method of claim 2 , wherein the antigen in the second influenza vaccine was prepared from an influenza virus that has never been passaged in eggs.

22. The method of claim 2 , wherein the first and/or the second influenza vaccine is adjuvanted.

23. The method of claim 2 , wherein the antigen from the second influenza vaccine is manufactured from a synthetic seed virus.

Assignees

• Seqirus Uk Ltd

Inventors

• Settembre Ethan
• Dormitzer Philip

Classifications

• A61K2039/525

  Virus · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K2039/5252

  inactivated (killed) · CPC title

• C12N2760/16121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title